Back to Press ReleaseDr. H. Fai Poon, CEO of Sirnaomics, took the stage at the Oligonucleotides & Peptides World Asia Congress 2026 held in Singapore on June 30.
In his keynote speech titled Innovative Delivery Platforms for siRNA Therapeutics, Dr. Poon presented Sirnaomics' proprietary PNP delivery platform to the global biotech community. He comprehensively shared the platform's clinical applications and disclosed Phase I and II human clinical data generated from the PNP platform, demonstrating its robust clinical translational potential.
(Rightmost: Dr. H Fai Poon, CEO of Sirnaomics)
Following the keynote, Dr. Poon joined the closing leadership panel discussion: Emerging RNA Modalities & What to Watch in the Next 3–5 Years. He engaged in in-depth dialogue alongside distinguished industry experts: Andy Xian Zeng, Co-Founder & CEO of Byterna Therapeutics, and Dr. Wonil Kim, CSO of Aston Sci.
All panelists reached a unanimous industry consensus:
Over the next three to five years, RNA therapeutics will evolve into a massive global market extending far beyond siRNA, delivering numerous transformative medical breakthroughs that benefit patients worldwide. We sincerely hope geopolitical tensions will not hinder global research, development, and accessibility of novel RNA medicines for all populations.
Leveraging our proprietary PNP delivery platform as a core competitive edge, Sirnaomics will continue advancing the global development of RNAi therapeutics to deliver revolutionary treatment options for patients around the world.
Sirnaomics Ltd.(HK: 2257), known as Asia's "First RNAi Therapeutics Stock," is a clinical-stage global biopharmaceutical company specializing in RNA interference technology. Utilizing its dual core technology platforms and diverse pipeline, the company is at the forefront of developing RNAi therapies to drive industry growth.
Sirnaomics has two proprietary delivery platforms:
- Polypeptide Nanoparticle (PNP) Platform: An extrahepatic delivery platform enabling precise targeting of tissues such as skin, adipose tissue, and muscle.
- GalAhead™ Delivery Platform: A liver-targeted delivery system with clear IP and long-acting administration capabilities.
The company is also an industry leader with its innovative linker-free, dual-target RNAi technology. Sirnaomics' robust pipeline addresses oncology, local fat reduction, medical aesthetics, and cardiovascular diseases, with multiple products in clinical trials. Beyond its internal development, Sirnaomics embraces an open-collaboration strategy, integrating its technology platforms to support the broader industry and benefit patients worldwide.
Previous
